How Risperdal Whistle-Blowers Made Millions From J&J

Hodgson Russ’s chairman, Daniel C. Oliverio, is quoted in the Bloomberg News article “How Risperdal Whistle-Blowers Made Millions From J&J,” which details the role Johnson & Johnson whistleblowers played in the government’s investigation of claims that the pharmaceutical giant illegally marketed the drug Risperdal for off-label uses. Johnson & Johnson eventually settled the investigation for approximately $2 billion, a portion of which went to the whistleblowers. Dan leads a team of Hodgson Russ attorneys that represents two of those whistleblowers.

Click here to read “How Risperdal Whistle-Blowers Made Millions From J&J.”